Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luana Maggiore

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecular Biotechnology|September 17, 2014
Comparison of colorimetric assays with quantitative amino acid analysis for protein quantification of Generalized Modules for Membrane Antigens (GMMA)Omar Rossi, Luana Maggiore, Francesca Necchi, et al.
International Journal of Medical Microbiology : IJMM|January 10, 2016
Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparationsLuana Maggiore, Lu Yu, Ulrich Omasits, et al.
Journal of Molecular and Cellular Cardiology|January 15, 2008
The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerizationSilvia Biocca, Ilaria Filesi, Ruggiero Mango, et al.
Plos One|June 16, 2012
High yield production process for Shigella outer membrane particlesFrancesco Berlanda Scorza, Anna Maria Colucci, Luana Maggiore, et al.
Scientific Reports|March 23, 2018
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel DiseaseJ Scott Crowe, Kevin J Roberts, Timothy M Carlton, et al.
Scientific Reports|October 1, 2021
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel diseaseKevin J Roberts, Marion F Cubitt, Timothy M Carlton, et al.
Drug Development and Industrial Pharmacy|November 6, 2018
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeysJ Scott Crowe, Kevin J Roberts, Timothy M Carlton, et al.
Scientific Reports|October 3, 2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis PatientsSuhail Nurbhai, Kevin J Roberts, Timothy M Carlton, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecular Biotechnology|September 17, 2014
Comparison of colorimetric assays with quantitative amino acid analysis for protein quantification of Generalized Modules for Membrane Antigens (GMMA)Omar Rossi, Luana Maggiore, Francesca Necchi, et al.
International Journal of Medical Microbiology : IJMM|January 10, 2016
Quantitative proteomic analysis of Shigella flexneri and Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) reveals highly pure preparationsLuana Maggiore, Lu Yu, Ulrich Omasits, et al.
Journal of Molecular and Cellular Cardiology|January 15, 2008
The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerizationSilvia Biocca, Ilaria Filesi, Ruggiero Mango, et al.
Plos One|June 16, 2012
High yield production process for Shigella outer membrane particlesFrancesco Berlanda Scorza, Anna Maria Colucci, Luana Maggiore, et al.
Scientific Reports|March 23, 2018
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel DiseaseJ Scott Crowe, Kevin J Roberts, Timothy M Carlton, et al.
Scientific Reports|October 1, 2021
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel diseaseKevin J Roberts, Marion F Cubitt, Timothy M Carlton, et al.
Drug Development and Industrial Pharmacy|November 6, 2018
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeysJ Scott Crowe, Kevin J Roberts, Timothy M Carlton, et al.
Scientific Reports|October 3, 2019
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis PatientsSuhail Nurbhai, Kevin J Roberts, Timothy M Carlton, et al.
Pageof 1